NO991194D0 - Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid - Google Patents

Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid

Info

Publication number
NO991194D0
NO991194D0 NO991194A NO991194A NO991194D0 NO 991194 D0 NO991194 D0 NO 991194D0 NO 991194 A NO991194 A NO 991194A NO 991194 A NO991194 A NO 991194A NO 991194 D0 NO991194 D0 NO 991194D0
Authority
NO
Norway
Prior art keywords
alfa
methoxyimino
azabicyclo
oct
controlled
Prior art date
Application number
NO991194A
Other languages
English (en)
Norwegian (no)
Other versions
NO991194L (no
Inventor
Susan Marie Milosovich
William Muldoon
Joseph Sauer
James Albert Napper
Laurence Rousseau
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of NO991194L publication Critical patent/NO991194L/no
Publication of NO991194D0 publication Critical patent/NO991194D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
NO991194A 1996-09-12 1999-03-11 Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid NO991194D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619074.9A GB9619074D0 (en) 1996-09-12 1996-09-12 Composition
PCT/GB1997/002418 WO1998010762A2 (en) 1996-09-12 1997-09-08 Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride

Publications (2)

Publication Number Publication Date
NO991194L NO991194L (no) 1999-03-11
NO991194D0 true NO991194D0 (no) 1999-03-11

Family

ID=10799833

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991194A NO991194D0 (no) 1996-09-12 1999-03-11 Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid

Country Status (22)

Country Link
EP (1) EP0929301A2 (cs)
JP (1) JP2001500150A (cs)
KR (1) KR20000036039A (cs)
CN (2) CN1235544A (cs)
AR (1) AR008176A1 (cs)
AU (1) AU724086B2 (cs)
BR (1) BR9711734A (cs)
CA (1) CA2265661A1 (cs)
CO (1) CO5031291A1 (cs)
CZ (1) CZ83299A3 (cs)
GB (1) GB9619074D0 (cs)
HU (1) HUP9904401A3 (cs)
ID (1) ID19589A (cs)
IL (1) IL128781A0 (cs)
MA (1) MA24359A1 (cs)
NO (1) NO991194D0 (cs)
NZ (1) NZ334268A (cs)
PE (1) PE2499A1 (cs)
PL (1) PL332074A1 (cs)
TR (1) TR199900505T2 (cs)
WO (1) WO1998010762A2 (cs)
ZA (1) ZA978133B (cs)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (fr) * 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
EP1061918A1 (en) * 1998-03-11 2000-12-27 Smithkline Beecham Plc Controlled release composition of (1-azabicyclo(2.2.2)oct-3-yl)acetonitrile monohydrochloride
DE19918325A1 (de) * 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
FR2796840B1 (fr) * 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques Comprimes faiblement doses et procede de preparation
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
PA8578501A1 (es) 2002-07-25 2005-02-04 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
KR101139744B1 (ko) 2003-04-25 2012-04-26 미쓰비시 타나베 파마 코퍼레이션 알킬렌 디옥시벤젠 유도체 함유 경구 투여용 조성물
US20070009596A1 (en) * 2003-05-14 2007-01-11 Bruschi Stefano D L Controlled drug release composition resistant to in vivo mechanic stress
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2005272347A (ja) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk 固形製剤の製造方法
ME01442B (me) 2004-08-13 2013-12-20 Boehringer Ingelheim Int Tabletna formulacija sa produženim otpuštanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatuivu so, postupak za proizvodnju iste i njena primjena
EA201001086A1 (ru) * 2004-08-13 2011-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0392803T3 (da) * 1989-04-13 2004-10-18 Beecham Group Plc Hidtil ukendte forbindelser
GB9409718D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (es) * 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.

Also Published As

Publication number Publication date
HUP9904401A2 (hu) 2000-06-28
IL128781A0 (en) 2000-01-31
NO991194L (no) 1999-03-11
GB9619074D0 (en) 1996-10-23
AR008176A1 (es) 1999-12-09
CZ83299A3 (cs) 1999-08-11
WO1998010762A2 (en) 1998-03-19
ZA978133B (en) 1999-04-12
PE2499A1 (es) 1999-03-24
CO5031291A1 (es) 2001-04-27
AU724086B2 (en) 2000-09-14
NZ334268A (en) 2000-10-27
TR199900505T2 (cs) 1999-06-21
BR9711734A (pt) 1999-08-24
JP2001500150A (ja) 2001-01-09
CA2265661A1 (en) 1998-03-19
PL332074A1 (en) 1999-08-30
EP0929301A2 (en) 1999-07-21
KR20000036039A (ko) 2000-06-26
CN1235544A (zh) 1999-11-17
WO1998010762A3 (en) 1998-06-04
CN1446535A (zh) 2003-10-08
ID19589A (id) 1998-07-23
MA24359A1 (fr) 1998-07-01
HUP9904401A3 (en) 2001-03-28
AU4128897A (en) 1998-04-02

Similar Documents

Publication Publication Date Title
NO991194D0 (no) Kontrollert-frigj°ring doseform av [R-(Z)-&lt;alfa&gt;-(metoksyimino)-&lt;alfa&gt;-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid
IL145071A0 (en) Fused ring compounds and pharmaceutical compositions containing the same
DE69514087D1 (de) Pharmazeutisch aktive substituierte aromatische verbindungen
IL137445A0 (en) Pharmaceutically active compounds and methods of use thereof
NO990944L (no) Tablett med kontrollert frigivelse av alfuzosinhydroklorid
HUP0004926A3 (en) 1-(n-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of the phenyl ring, pharmaceutical compositions containing them and their use
PL356769A1 (en) Novel heterocyclic compounds and salts thereof and medicinal use of the same
EA200200571A1 (ru) Новая композиция и ее применение
HU9800112D0 (en) Biphenyl-sulfonyl-substituted heterocyclic compounds of fife-membered ring, their production and use
HUP9901590A3 (en) Substituted aza- and diazacycloheptane and cyclooctane derivatives, use thereof, pharmaceutical compositions containing these compounds
EA200200119A1 (ru) β-КАРБОЛИНОВЫЕ ЛЕКАРСТВЕННЫЕ ПРОДУКТЫ
EP1115396A4 (en) PHARMACEUTICALLY ACTIVE COMPOUNDS, AND METHODS OF USE THEREOF
HUP9902166A3 (en) Substituted benzamide derivatives having anticonvulsant activity, preparation and use thereof, pharmaceutical compositions containing these compounds
ES2171018T3 (es) Uso de agentes inmunomoduladores.
NO986086D0 (no) FremgangsmÕte for fremstilling av 17-estere av 9&lt;alfa&gt;,21-dihalo-pregnan-11
EE200100656A (et) Kristallilise asabitsüklo(2,2,2)oktaan-3-amiintsitraadi polümorfid ja nende ravimsegud
ITMI911604A0 (it) Procedimento per la preparazione della n- (2,6-diclorofenil) -n-feniln- (cloroacetil) - ammina
NO992668D0 (no) Topisk preparat for innf°ring av farmas°ytisk aktive peptidforbindelser i levende organismer
NO910372L (no) Fremgangsmaate for fremstilling av heksahydropyrrolo(2,3-b)indolkarbamater-, urea-, amider og beslektede forbindelser og deres anvendelse som medikamenter.
ATE232103T1 (de) Osteoblastenspezifische mitogene und diese verbindungen enthaltende arzneimittel
TR199900141T2 (xx) Bunama tedavisi ve/veya profilaksisi i�in form�lasyon.
NO20010195D0 (no) Fremgangsmåte for behandling
IL135168A0 (en) Novel pharmaceutically active compounds, their preparation and use as ece-inhibitors
GB9821966D0 (en) Process for the preparation of orally active cephalosporin antibiotic-cefixim
GB9821967D0 (en) Process for the preparation of orally active cephalosporin antibiotic-cefixim